Analogs for novel targets such as amylin, leptin, GLP-1 MC4R, oxyntomodulin, neuropeptide Y antagonists, cannabinoid type-1 receptor blockers, MetAP2 inhibitors, lipase inhibitors and anti-obesity vaccines are currently being studied and it is predicted that the combined use of two or more classes of drugs involving various pathways might be beneficial (8). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.